New data from Michelangelo Foundation’s NeoTRIP trial discussed during ESMO Congress

No Event-free survival improvement by addition of atezolizumab to neoadjuvant chemotherapy in NeoTRIP study but in a subset of triple negative breast cancer with a newly identified predictor restricted to benefit from the anti-PD-L1 antibody